A new phase 1 clinical trial of a potential vaccine for the SARS-CoV2 coronavirus began on Monday in Seattle, with the first person to enroll in the trial receiving the vaccine.
The vaccine, mRNA-1273, was developed by biotechnology company Moderna in combination with researchers from the National Institutes of Health (NIH). The trial is being conducted at Kaiser Permanente Washington Health Research Institute in Seattle.
“This study is the first step in the clinical development of an mRNA vaccine against SARS-CoV-2, and we expect it to provide important information about safety and immunogenicity,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna in a press release. He added that Moderna is already working with the FDA and other organizations to prepare for a phase 2 trial, which would involve larger numbers of patients.
The start of the trial comes just 65 days after Chinese authorities sequenced the SARS-CoV2 coronavirus. Just 2 days after that, researchers at the Vaccine Research Center at the NIH finalized the design of the vaccine and began to manufacture it, finishing the first batch on February 7th. On February 24th after analytical testing, the company shipped it to the NIH.
Although the design and production of the prospective vaccine was incredibly fast, evaluation of it will take considerable time. All of the participants will be followed for 12 months after the second vaccination to collect the data researchers initially need to figure out whether it is safe and effective.
Click on the comment box below and leave us your thoughts. Thank you